Lanoteplase

Targets (17)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Lanoteplase
Accession Number
DB06245
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
BMS-200980 / SUN 9216 / SUN-9216
Categories
UNII
5U26HTF8RV
CAS number
171870-23-8

Pharmacology

Indication

Investigated for use/treatment in myocardial infarction.

Pharmacodynamics
Not Available
Mechanism of action

Lanoteplase is a second generation derivative of alteplase, and a third generation recombinant plasminogen activator made from a deletion and point mutant of tissue type-plasminogen activator (t-PA). Lanoteplase has a longer half life than alteplase. Lanoteplase is a serine protease that binds to fibrin in a thrombus (blood clot)and cleaves the Arg-Val bond in plasminogen, producing active plasmin. Plasmin is an enzyme that degrades plasma proteins such as fibrin clots to clear blocked blood vessels that cause myocardial infarction (heart attack) or stroke.

TargetActionsOrganism
UUrokinase plasminogen activator surface receptorNot AvailableHumans
UFibrinogen alpha chainNot AvailableHumans
UKallikrein-1Not AvailableHumans
ULaminin subunit alpha-5Not AvailableHumans
UCoagulation factor XNot AvailableHumans
UFibronectinNot AvailableHumans
UPlasminogen activator inhibitor 2Not AvailableHumans
UTetranectinNot AvailableHumans
UKeratin, type II cytoskeletal 8Not AvailableHumans
UAnnexin A2Not AvailableHumans
ULaminin subunit beta-1Not AvailableHumans
ULaminin subunit gamma-1Not AvailableHumans
ULaminin subunit alpha-1Not AvailableHumans
UCalreticulinNot AvailableHumans
UCalnexinNot AvailableHumans
UProlow-density lipoprotein receptor-related protein 1Not AvailableHumans
ULaminin subunit alpha-3Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
Acetylsalicylic acidThe risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Lanoteplase.
AlogliptinThe risk or severity of angioedema can be increased when Alogliptin is combined with Lanoteplase.
AlteplaseThe risk or severity of angioedema can be increased when Alteplase is combined with Lanoteplase.
AmediplaseThe risk or severity of angioedema can be increased when Lanoteplase is combined with Amediplase.
AMG-222The risk or severity of angioedema can be increased when AMG-222 is combined with Lanoteplase.
AnagliptinThe risk or severity of angioedema can be increased when Lanoteplase is combined with Anagliptin.
AnistreplaseThe risk or severity of angioedema can be increased when Anistreplase is combined with Lanoteplase.
Azilsartan medoxomilThe risk or severity of angioedema can be increased when Lanoteplase is combined with Azilsartan medoxomil.
BenazeprilThe risk or severity of angioedema can be increased when Benazepril is combined with Lanoteplase.
BenazeprilatThe risk or severity of angioedema can be increased when Lanoteplase is combined with Benazeprilat.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Zeymer U, Neuhaus KL: Lanoteplase: a viewpoint by Uwe Zeymer and Karl-Ludwig Neuhaus. BioDrugs. 2000 Mar;13(3):225-6. [PubMed:18034528]
  2. Bhana N, Spencer CM: Lanoteplase. BioDrugs. 2000 Mar;13(3):217-24. [PubMed:18034526]
  3. Nordt TK, Moser M, Kohler B, Kubler W, Bode C: Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost. 1999 Sep;82 Suppl 1:121-3. [PubMed:10695501]
External Links
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Details1. Urokinase plasminogen activator surface receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Urokinase plasminogen activator receptor activity
Specific Function
Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-...
Gene Name
PLAUR
Uniprot ID
Q03405
Uniprot Name
Urokinase plasminogen activator surface receptor
Molecular Weight
36977.62 Da
Details2. Fibrinogen alpha chain
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function ...
Gene Name
FGA
Uniprot ID
P02671
Uniprot Name
Fibrinogen alpha chain
Molecular Weight
94972.455 Da
Details3. Kallikrein-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name
KLK1
Uniprot ID
P06870
Uniprot Name
Kallikrein-1
Molecular Weight
28889.425 Da
Details4. Laminin subunit alpha-5
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
Gene Name
LAMA5
Uniprot ID
O15230
Uniprot Name
Laminin subunit alpha-5
Molecular Weight
399733.48 Da
Details5. Coagulation factor X
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
Details6. Fibronectin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protease binding
Specific Function
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, an...
Gene Name
FN1
Uniprot ID
P02751
Uniprot Name
Fibronectin
Molecular Weight
262623.095 Da
Details7. Plasminogen activator inhibitor 2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.
Gene Name
SERPINB2
Uniprot ID
P05120
Uniprot Name
Plasminogen activator inhibitor 2
Molecular Weight
46595.84 Da
Details8. Tetranectin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Kringle domain binding
Specific Function
Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis.
Gene Name
CLEC3B
Uniprot ID
P05452
Uniprot Name
Tetranectin
Molecular Weight
22536.665 Da
Details9. Keratin, type II cytoskeletal 8
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.
Gene Name
KRT8
Uniprot ID
P05787
Uniprot Name
Keratin, type II cytoskeletal 8
Molecular Weight
53703.76 Da
Details10. Annexin A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
S100 protein binding
Specific Function
Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress resp...
Gene Name
ANXA2
Uniprot ID
P07355
Uniprot Name
Annexin A2
Molecular Weight
38603.63 Da
Details11. Laminin subunit beta-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
Gene Name
LAMB1
Uniprot ID
P07942
Uniprot Name
Laminin subunit beta-1
Molecular Weight
198036.545 Da
Details12. Laminin subunit gamma-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Glycosphingolipid binding
Specific Function
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
Gene Name
LAMC1
Uniprot ID
P11047
Uniprot Name
Laminin subunit gamma-1
Molecular Weight
177601.19 Da
Details13. Laminin subunit alpha-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Glycosphingolipid binding
Specific Function
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
Gene Name
LAMA1
Uniprot ID
P25391
Uniprot Name
Laminin subunit alpha-1
Molecular Weight
337080.89 Da
Details14. Calreticulin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently wit...
Gene Name
CALR
Uniprot ID
P27797
Uniprot Name
Calreticulin
Molecular Weight
48141.2 Da
Details15. Calnexin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembl...
Gene Name
CANX
Uniprot ID
P27824
Uniprot Name
Calnexin
Molecular Weight
67567.695 Da
Details16. Prolow-density lipoprotein receptor-related protein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance...
Gene Name
LRP1
Uniprot ID
Q07954
Uniprot Name
Prolow-density lipoprotein receptor-related protein 1
Molecular Weight
504601.695 Da
Details17. Laminin subunit alpha-3
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
Gene Name
LAMA3
Uniprot ID
Q16787
Uniprot Name
Laminin subunit alpha-3
Molecular Weight
366646.12 Da

Drug created on March 19, 2008 10:19 / Updated on December 02, 2019 07:20